Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (46) Filters Reset all × Publication × 5/6 nephrectomy (Nx) rat × DIO rat × Gene expression × Histopathology score × Nicotine × Y2 receptor × Search × Resource type Data presentation (0) Poster (49) Publication (46) 3D imaging video (0) Webinar (4) Category × Disease model (118) Cardiovascular disease (3) AngII mouse (0) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (1) DIO-PCK9-AAV mouse (0) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (18) Alzheimer's disease models (5) CNS activation (7) Drug distribution (1) Gene expression (0) Gene therapy (0) Parkinson's disease models (4) Diabetes (28) db/db mouse (14) Non-obese diabetic (NOD) mouse (3) ZDF rat (10) Inflammatory bowel disease (0) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (0) Idiopathic pulmonary fibrosis (0) BLEO-IPF mouse (0) Chronic BLEO-IPF mouse (0) HFD-BLEO-IPF mouse (0) Kidney disease (7) Acute kidney injury (1) Bilateral ischemia reperfusion injury (bIRI) mouse (0) Unilateral ischemia reperfusion injury (uIRI) mouse (1) Chronic kidney disease (2) Anti-GBM glomerulonephritis mouse (0) Adenine diet-induced (ADI) nephropathy mouse (1) Polycystic kidney disease (PCK) rat (0) Unilateral ureteral obstruction (UUO) mouse (1) 5/6 nephrectomy (Nx) rat (1) Diabetic kidney disease (5) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (3) ZSF-1 rat (0) Knock-out mouse models (6) Metabolic dysfunction-associated steatohepatitis (34) GAN DIO-MASH mouse (9) GAN DIO-MASH-HCC mouse (3) GAN ob/ob-MASH mouse (2) CDAA-HFD mouse (3) CDAA-HFD rat (3) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (12) Obesity (46) Bariatric surgery (10) DIO mouse (21) DIO rat (14) ob/ob mouse (8) Therapeutic Area (140) Alzheimer's disease (5) Alcoholic steatohepatitis (2) Cardiovascular disease (3) Chronic kidney disease (8) Cholangiopathy (1) Diabetes (52) Diabetic cardiomyopathy (1) Diabetic kidney disease (8) Hepatocellular carcinoma (4) Idiopathic pulmonary fibrosis (0) Inflammatory bowel disease (0) Metabolic dysfunction-associated steatohepatitis (41) Obesity (70) Parkinson's disease (4) Target (88) Alpha-synuclein (0) Autotaxin (0) Beta amyloid (0) Acetyl-CoA carboxylase (0) Amylin receptor (2) Angiotensin converting enzyme (ACE) (3) AMPK (1) ASBT (1) CB1 receptor (3) CCK receptor (4) D2 receptor (1) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (2) FXR (6) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (4) GLP-1 receptor (47) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (0) 5-HT2C receptor (1) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (2) Monoamine transporter (1) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (0) PICK1 (1) PPAR (11) PSD-95 (1) Renin–angiotensin system (1) Secretin receptor (1) SGLT-2 (3) TAAR1 (1) TGF-beta (0) TGR5 (0) THR-ß receptor (1) Y2 receptor (3) Compound (83) Aducanumab biosimilar (1) Adeno-associated virus (AAV)-mediated gene therapy (0) A3907 (1) Adrenomedullin (1) Alk5 inhibitor (0) ALT-801 (1) Amylin (1) Amylin receptor agonist (0) BLD-0409 (0) Bromocriptine (1) CHS-131 (1) Captopril (1) Cilofexor (0) Cotadutide (1) DA-1241 (0) Dapagliflozin (1) Dietary intervention (2) Exenatide (6) Elafibranor (5) Empagliflozin (3) Exendin-4 analogues (1) FGF21 (2) Firsocostat (0) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (2) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (0) GUBamy (0) GS-834356 (0) HSD17b13 inhibitor (0) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (2) INT-787 (0) Lanifibranor (2) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (2) Lorcaserin (1) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (7) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (1) Rimonabant (2) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (0) Semaglutide (8) SER140 (1) Setmelanotide (1) Sibutramine (2) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) Tirzepatide (0) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (147) 3D imaging (19) Adeno-associated virus (AAV)-mediated gene delivery (3) Atherosclerotic plaques (0) Beta-cell mass (11) Blood pressure (0) Body composition (10) Body weight (55) Blood biochemistry (33) Bariatric surgery (12) Bioinformatics (57) c-Fos activation (13) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (21) Drug distribution (1) Energy expenditure monitoring (3) Echocardiography (ECG) (2) Flow cytometry (0) Gut biopsy (6) Glomerular filtration rate (GFR) (3) Gastric emptying (3) Gut morphometry (9) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (27) Heart morphometry (1) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (49) Immunohistochemistry (IHC) (55) In situ hybridization (ISH) (13) Insulin tolerance test (ITT) (2) Kidney biopsy (1) Kidney morphometry (8) Lung functional test (0) Light sheet fluorescence microscopy (LSFM) (22) Liver biopsy (31) Liver morphometry (29) Lung biochemistry (0) Laser-capture microdissection (LCM) (8) Magnetic resonance imaging (MRI) (1) Microbiomics (5) Micro-computed tomography (micro-CT) (0) Neurobehavior (6) Next-generation sequencing (15) Nephrectomy (7) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (8) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (31) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (44) Single-cell RNA sequencing (2) Single-nucleus RNA sequencing (1) siRNA (1) StreaMLine (0) Surgery (8) Spirometry (0) Stereology (29) Stereotaxic injection (0) Ultrasound imaging (0) Urine biochemistry (4) Vasculature (1) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (0) Whole-brain in situ hybridization (0) Species (120) Hamster (1) Human (22) Mouse (84) Minipig (1) Non-human primate (3) Pig (2) Rat (27) Show (46) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × Publication × 5/6 nephrectomy (Nx) rat × DIO rat × Gene expression × Histopathology score × Nicotine × Y2 receptor × 46 resource library items found PublicationAn unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) PublicationParaoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis PublicationDietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationSemaglutide reduces tumor burden in the GAN diet‑induced obese and biopsy‑confirmed mouse model of NASH‑HCC with advanced fibrosis PublicationGLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity PublicationA3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans PublicationHepatoprotective effects of the long-acting FGF21 analogue PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationFASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models PublicationGIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior PublicationNephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease PublicationStructurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease PublicationEffects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis PublicationHepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationPeptide-YY3-36/glucagon-like peptide-1 combination treatment of obese-diabetic mice improves insulin sensitivity associated with recovered pancreatic ß-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries PublicationTherapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease PublicationEmpagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH PublicationCharacterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice PublicationActivation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis PublicationTranscriptomic changes in pancreatic islets, adipose and liver after Roux-en-Y gastric bypass in a diet-induced obese rat model PublicationIdentification and metabolic profiling of a novel human gut-derived LEAP2 fragment PublicationDual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative PublicationHuman translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis PublicationResolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis PublicationActivation of adenosine monophosphate-activated protein kinase reduces the onset of diet-induced hepatocellular carcinoma in mice Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650